BIOLOGY.DIGITAL
Back to Glossary

CRISPR Off-Target Scoring

Acronym for: CFD / MIT / Elevation Off-Target Prediction

Also known as: gRNA Specificity Modeling, GUIDE-seq / CHANGE-seq Validation, Cas9 Cleavage Kinetics Prediction

Algorithmic models and genome-wide biophysical alignment tools that calculate the probability of a CRISPR-Cas nuclease (Cas9, Cas12a, base editor, or prime editor) inducing unintended double-strand breaks or deamination edits at mismatched genomic loci.

**Quick Spec:** - Term: CRISPR Off-Target Scoring - Standard: CFD / MIT / Elevation Off-Target Prediction - Where you'll use it in your R&D stack: Cell & Gene Therapy, Agricultural Genome Editing, Functional Genomics - Platforms we've benchmarked for our readers: CRISPOR, Cas-OFFinder, Benchling CRISPR

Architectural Role in Modern Life Science R&D

When designing guide RNAs (sgRNAs) for ex vivo or in vivo therapeutic gene editing (such as sickle cell disease or transthyretin amyloidosis), even a 0.1% cleavage rate at a 3-mismatch locus inside a tumor suppressor gene (like TP53) can trigger chromosomal translocations or oncogenic clonal expansion. Computational off-target scoring tools (such as CRISPOR, Cas-OFFinder, CHOPCHOP, and deep learning CFD/Elevation scores) scan the entire reference human genome (GRCh38) alongside patient-specific SNP variants to rank candidate protospacers before orthogonal wet-lab verification via GUIDE-seq, CIRCLE-seq, or rhAmpSeq. Why does this matter for your lab? If you're scaling CRISPR Off-Target Scoring in production, we've found you can't treat it as a black box. You'll need tight wet-lab calibration, and we always recommend validating your pipeline against orthogonal assays before you lock in your budget.

Evaluation & Wet-Lab Integration Checklist

How do you evaluate CRISPR Off-Target Scoring without wasting six months? Start small. When we audit R&D informatics teams, we tell you to test three things first: prospective wet-lab accuracy (like SPR or Cryo-EM), native API sync with your ELN, and containerized GPU costs. Don't skip the retrospective benchmark. It's the fastest way to see if a vendor's model actually works on your proprietary targets.

Context

When designing guide RNAs (sgRNAs) for ex vivo or in vivo therapeutic gene editing (such as sickle cell disease or transthyretin amyloidosis), even a 0.1% cleavage rate at a 3-mismatch locus inside a tumor suppressor gene (like TP53) can trigger chromosomal translocations or oncogenic clonal expansion. Computational off-target scoring tools (such as CRISPOR, Cas-OFFinder, CHOPCHOP, and deep learning CFD/Elevation scores) scan the entire reference human genome (GRCh38) alongside patient-specific SNP variants to rank candidate protospacers before orthogonal wet-lab verification via GUIDE-seq, CIRCLE-seq, or rhAmpSeq. Why does this matter for your lab? If you're scaling CRISPR Off-Target Scoring in production, we've found you can't treat it as a black box. You'll need tight wet-lab calibration, and we always recommend validating your pipeline against orthogonal assays before you lock in your budget.

Examples

  • 1Using Cas-OFFinder on GPU to enumerate all potential genomic sites with up to 5 mismatches and 2 DNA/RNA bulges for a therapeutic adenine base editor targeting PCSK9.
  • 2Designing multiplex CRISPR knockouts in Benchling CRISPR using Doench Rule Set 3 on-target efficiency scores paired with CFD off-target specificity filters.
  • 3Submitting empirical GUIDE-seq and computational off-target nomination packages to the FDA for an IND filing following the 2024 FDA Human Gene Therapy Products Incorporating Human Genome Editing guidance.

Implementing Agents

AI agents that implement or utilize CRISPR Off-Target Scoring:

Common Industries

Cell & Gene TherapyAgricultural Genome EditingFunctional Genomics

Related Terms

Learn More

Verified References & Citations (2)

  1. [1]

    Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.

  2. [2]

    FDA guidance on human gene therapy products incorporating human genome editing requires orthogonal in silico and cellular off-target assessment.

Last updated: March 1, 2026

Ask AI